Needham & Company Reiterates a 'Strong Buy' on SYNNEX Corp (SNX); Posts Solid F1Q Despite Acquisitions; Excluding Minor Impact From Events In Japan Recovering IT Market Evident
Get Alerts SNX Hot Sheet
Price: $250.14 -0.25%
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Needham & Company reiterates a 'Strong Buy' on SYNNEX Corp. (NYSE: SNX), PT $42.
Needham analyst says, "Although the horrible events in Japan have had a slight impact to the business, we expect only a temporary delay in accretion due to SNX’s history of execution and broad-based strength in NA & Canada. We would be a buyer on any pullbacks...SNX expects $2.44-2.56B in revenue, net income of $28.6-29.9M and EPS of $0.77-0.81 vs. our $2.52B and $0.81 forecast. Adjusting estimates for F2Q to $2.5B and $0.79. F11 becomes $10.4B and $3.58, up from $10.4B and $3.53. Our F12 estimate becomes $11B and $4.06 from $10.6B and $3.62."
For more ratings news on SYNNEX Corp. click here and for the rating history of SYNNEX Corp. click here.
Shares of SYNNEX Corp. closed at $34.15 yesterday.
Needham analyst says, "Although the horrible events in Japan have had a slight impact to the business, we expect only a temporary delay in accretion due to SNX’s history of execution and broad-based strength in NA & Canada. We would be a buyer on any pullbacks...SNX expects $2.44-2.56B in revenue, net income of $28.6-29.9M and EPS of $0.77-0.81 vs. our $2.52B and $0.81 forecast. Adjusting estimates for F2Q to $2.5B and $0.79. F11 becomes $10.4B and $3.58, up from $10.4B and $3.53. Our F12 estimate becomes $11B and $4.06 from $10.6B and $3.62."
For more ratings news on SYNNEX Corp. click here and for the rating history of SYNNEX Corp. click here.
Shares of SYNNEX Corp. closed at $34.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- Kotak Upgrades Narayana Hrudayalaya Ltd (NARH:IN) to Buy (1)
- HSBC Downgrades Kakao Corp. (035720:KS) to Hold
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share